Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 10/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227356 | 0.87 | KMT2A (0.51) | NPC1MEN1KMT2ACPB2SMN1; SMN2 | |
| SCHEMBL4232549 | 0.77 | KMT2A (0.49) | NPC1MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL2396658 | 0.76 | KMT2A (0.49) | NPC1MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL1748179 | 0.76 | NPC1 (0.43) | NPC1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL6031378 | 0.76 | NPC1 (0.58) | NPC1MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL1748086 | 0.76 | NPC1 (0.58) | NPC1MEN1KMT2ASMN1; SMN2CYP1A2 | |
| SCHEMBL18065697 | 0.75 | SMN1; SMN2 (0.57) | NPC1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL4232005 | 0.75 | NPC1 (0.43) | NPC1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL13744649 | 0.72 | NPC1 (0.50) | NPC1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL4221489 | 0.71 | KMT2A (0.52) | NPC1MEN1KMT2ARAB9AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | NPC1 187/4885MEN1 4348/4885KMT2A 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.